NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free PHAT Stock Alerts $10.62 -0.43 (-3.89%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$10.42▼$11.2250-Day Range$6.21▼$11.0552-Week Range$6.07▼$17.02Volume886,406 shsAverage Volume852,987 shsMarket Capitalization$621.06 millionP/E RatioN/ADividend YieldN/APrice Target$21.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Phathom Pharmaceuticals alerts: Email Address Phathom Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside100.9% Upside$21.33 Price TargetShort InterestBearish40.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.39Based on 14 Articles This WeekInsider TradingSelling Shares$30.20 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.22) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.82 out of 5 starsMedical Sector686th out of 938 stocksPharmaceutical Preparations Industry306th out of 417 stocks 3.4 Analyst's Opinion Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.33, Phathom Pharmaceuticals has a forecasted upside of 100.9% from its current price of $10.62.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted40.11% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 13, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 20.42%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAT. Previous Next 1.9 News and Social Media Coverage News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,202,386.00 in company stock.Percentage Held by Insiders27.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.22) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More PHAT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAT Stock News HeadlinesMarch 27, 2024 | insidertrades.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 16,851 SharesMarch 28, 2024 | stockhouse.comPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"March 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 28, 2024 | investing.comPhathom Pharmaceuticals CEO sells shares worth over $153,000March 26, 2024 | finance.yahoo.comPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”March 25, 2024 | finance.yahoo.comSIGA Names Larry Miller General CounselMarch 23, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from Needham & Company LLCMarch 23, 2024 | markets.businessinsider.comPositive Prescription Trends and Resilience Prompt Buy Rating for Phathom PharmaceuticalsMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 19, 2024 | americanbankingnews.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reiterated at Needham & Company LLCMarch 18, 2024 | seekingalpha.comPhathom: Undervalued Biotech With Possible GERD Treatment Label ExpansionMarch 16, 2024 | finance.yahoo.comPHAT Apr 2024 10.000 callMarch 9, 2024 | seekingalpha.comPhathom Pharmaceuticals, Inc. (PHAT) Q4 2023 Earnings Call TranscriptMarch 9, 2024 | markets.businessinsider.comMaintaining Neutral on Phathom Pharmaceuticals Amid Voquezna Launch UncertaintiesMarch 8, 2024 | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)March 8, 2024 | finance.yahoo.comQ4 2023 Phathom Pharmaceuticals Inc Earnings CallMarch 7, 2024 | markets.businessinsider.comBuy Rating on Phathom Pharmaceuticals Amid Strong Voquezna Launch DemandMarch 7, 2024 | finance.yahoo.comPhathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...March 7, 2024 | investorplace.comPHAT Stock Earnings: Phathom Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023March 7, 2024 | globenewswire.comPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comPreview: Phathom Pharmaceuticals's EarningsMarch 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Pacira Pharmaceuticals (PCRX)February 29, 2024 | globenewswire.comPhathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024February 23, 2024 | markets.businessinsider.comStrong Market Uptake of Phathom Pharmaceuticals’ V oquezna Spurs Buy RatingFebruary 22, 2024 | benzinga.comPhathom Pharmaceuticals Stock (NASDAQ:PHAT) Insider TradesFebruary 22, 2024 | benzinga.comPhathom Pharmaceuticals Stock (NASDAQ:PHAT) Dividends: History, Yield and DatesSee More Headlines Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees452Year FoundedN/APrice Target and Rating Average Stock Price Target$21.33 High Stock Price Target$28.00 Low Stock Price Target$10.00 Potential Upside/Downside+100.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net MarginsN/A Pretax Margin-29,558.95% Return on EquityN/A Return on Assets-63.40% Debt Debt-to-Equity Ratio5.56 Current Ratio10.25 Quick Ratio10.22 Sales & Book Value Annual Sales$680,000.00 Price / Sales913.32 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-8.36Miscellaneous Outstanding Shares58,480,000Free Float42,630,000Market Cap$621.06 million OptionableOptionable Beta0.63 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMs. Terrie J. Curran (Age 55)President, CEO & Director Comp: $1.11MMr. David A. Socks (Age 49)Co-Founder & Director Comp: $58.78kDr. Azmi Nabulsi M.D. (Age 65)M.P.H., Co-Founder & COO Comp: $815.21kMs. Molly Henderson CPA (Age 53)MBA, Chief Financial & Business Officer Comp: $671.27kDr. Aditya Kohli Ph.D. (Age 35)Co-Founder Comp: $319.65kMr. Lawrence Miller Esq.J.D., General Counsel & SecretaryMr. Tom HarrisChief Development Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMr. Martin J. GilliganChief Commercial OfficerMore ExecutivesKey CompetitorsOlema PharmaceuticalsNASDAQ:OLMACogent BiosciencesNASDAQ:COGTSIGA TechnologiesNASDAQ:SIGANuvation BioNYSE:NUVBCalliditas Therapeutics AB (publ)NASDAQ:CALTView All CompetitorsInsiders & InstitutionsTerrie CurranSold 16,851 sharesTotal: $153,512.61 ($9.11/share)Vanguard Group Inc.Bought 33,767 shares on 3/11/2024Ownership: 3.345%Wellington Management Group LLPBought 54,581 shares on 3/5/2024Ownership: 0.270%Goldman Sachs Group Inc.Bought 71,711 shares on 3/1/2024Ownership: 0.367%Public Employees Retirement System of OhioBought 29,669 shares on 2/16/2024Ownership: 0.067%View All Insider TransactionsView All Institutional Transactions PHAT Stock Analysis - Frequently Asked Questions Should I buy or sell Phathom Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHAT shares. View PHAT analyst ratings or view top-rated stocks. What is Phathom Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 12 month price objectives for Phathom Pharmaceuticals' shares. Their PHAT share price targets range from $10.00 to $28.00. On average, they predict the company's share price to reach $21.33 in the next year. This suggests a possible upside of 100.9% from the stock's current price. View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts. How have PHAT shares performed in 2024? Phathom Pharmaceuticals' stock was trading at $9.13 at the start of the year. Since then, PHAT shares have increased by 16.3% and is now trading at $10.62. View the best growth stocks for 2024 here. When is Phathom Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PHAT earnings forecast. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.92) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.93 million. During the same period last year, the firm earned ($1.33) EPS. What ETFs hold Phathom Pharmaceuticals' stock? ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED). When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 7,900,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI served as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.42%), Vanguard Group Inc. (3.35%), Avidity Partners Management LP (3.01%), Gilder Gagnon Howe & Co. LLC (2.54%), Decheng Capital LLC (1.48%) and Catalys Pacific LLC (1.26%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHAT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.